ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms ...

Eli Lil­ly re­port­ed the first Phase 3 da­ta for its oral GLP-1 or­for­glipron Thurs­day morn­ing, say­ing the drug suc­ceed­ed in a type 2 di­a­betes tri­al … ...

XYNGARI™ Phase 3 STAR-1 Topline Week 4 Efficacy Results In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count ...